
LIMS & Lab Informatics
LIMS implementations on LabVantage, STARLIMS, and Benchling: sample tracking, instrument integration, and GLP audit trail per experiment.
Lab informatics, bioinformatics, AI discovery, and GxP-aligned translational platforms, shipped by senior teams, with the IND-ready evidence pack in the box.

Everything you need to run a wet lab, build reproducible bioinformatics, ship safe AI for discovery, and stand up GxP-clean translational platforms, under one accountable senior pod.

LIMS implementations on LabVantage, STARLIMS, and Benchling: sample tracking, instrument integration, and GLP audit trail per experiment.

Reproducible NGS, variant calling, RNA-seq, and single-cell pipelines on Nextflow / Snakemake, version-pinned, gated in CI, runnable on AWS or DNAnexus.

ELN platforms on Benchling, LabArchives, and bespoke estates: structured templates, GLP-ready audit trails, and integration with LIMS and analytics.

Target identification, hit-to-lead generative chemistry, structural AI, and ADMET prediction, with eval harnesses that clear scientific review.

Petabyte-scale data lakes for omics, imaging, and assay readouts: FAIR-aligned, compute that spins up to genome-wide and back down.

Translational platforms bridging discovery to clinic: biomarker pipelines, patient-data integration, and IND-ready evidence emission.
Reproducible pipelines, GLP audit trails, and IND-ready evidence ship with the build, not months after the agency interaction. The result: 5× faster target-to-lead and INDs cleared on first review.
Hand-written, photocopied for QA, indefensible in an FDA audit years later.
One scientist's laptop script, irreproducible once they move teams.
Single-workstation runs and shared-server queues, weeks per genome-wide study.
Wet lab, omics, imaging, and clinical in separate systems, every question takes months.
Structured templates, e-signatures, and a per-experiment audit log that holds up years later.
Pinned-container Nextflow / Snakemake pipelines, every run reproducible to the byte.
Auto-scaling on AWS / DNAnexus / Azure: petabyte lakes, GPU clusters, FinOps in one dashboard.
Wet lab, omics, imaging, and translational data in one FAIR lakehouse, answers in hours, not months.
Selected programmes across six modalities, anonymised where required, specific on the outcome.
End-to-end platform across wet lab, vector analytics, biomarkers, and clinical data, built to carry a Phase II IND across three indications.

GMP-clean batch records, COA generation, and chain-of-custody for autologous therapies.

Generative models for hit expansion with ADMET prediction wired in, scientific advisory cleared on first pass.

Variant pipelines, ACMG classification, and reporting at 100k-sample scale on AWS.

Phage display sequencing pipelines and structure-based filtering wired into the wet-lab loop.

Schrödinger / Cresset workflows on auto-scaling clusters, cut compute spend by 41% in year one.

Lab informatics, bioinformatics, computational chemistry, and data lakes, wired into one FAIR-aligned surface.
Connected. Unified. Audit-ready.
Pinned-container, Git-tracked Nextflow / Snakemake pipelines, every run reproducible to the byte.
ELN-first informatics with e-signatures and per-step audit trails, QA reviews artefacts that already exist.
Auto-scaling clusters for NGS, AI, and chem on AWS / DNAnexus / Azure, FinOps in the same dashboard.
Every engagement walks the same path, sized to your problem, but with the same verification gates baked in.
Two-week paid sprint. Architect-led. Output: regulator map, costed roadmap, signed scope.
Pod composition, sequenced milestones, change-control governance, and risk register.
Reference architecture, threat model, design system, and acceptance criteria locked.
Weekly demos, trunk-based, CI/CD from day one. Code reviewed against spec at every gate.
Unit, integration, e2e, security, performance, and accessibility, automated and gated.
Blue-green or canary, observability live before launch, rollback rehearsed.
Managed services or hypercare hand-off. Defined SLOs, named on-call, monthly reviews.
Success stories
BritonOne Technology is a full-cycle engineering company that builds and operates production software for regulated estates. Since 2017, we have shipped programmes that clear audit on the first pass across banking, insurance, wealth, healthcare, and biotech. Our teams pair deep domain knowledge with disciplined engineering, treating compliance, security, and resilience as first-class deliverables. From architecture through to live operations, we stay accountable for the systems we build, measuring success by uptime, audit outcomes, and defensible business results.
We don't compete on lowest day-rate. We compete on shipped outcomes inside environments that have to clear audit.
Every engineer on every engagement is at least senior, typically eight to fifteen years deep in their craft. No bench rotations, no junior pyramid hidden behind a glossy proposal, no bait-and-switch after contract signature. The architect who scoped your engagement is the same person committing code by week three.
FCA, PRA, EBA, BaFin, FINMA, HIPAA, SOC 2 Type II: every framework we work under is treated as a design constraint from day one, not a final-stage gate. Evidence trails, model-risk packs, change-control artefacts, and pen-test reports ship alongside the code, ready for second-line review without a remediation sprint.
Small pods of three to seven engineers, each with a named delivery lead who owns scope, schedule, and outcomes from kickoff to hand-off, never a faceless team you have to chase for an answer. Weekly demos run against the signed scope, frequent verification gates catch regressions early, and quarterly outcome reviews measure real progress against the original business case rather than a moving target. Together those rituals catch scope drift before it has any chance to compound, so programmes that should take six months don't quietly stretch into eighteen, budgets stay anchored to what was agreed, and every milestone ships with a written, testable definition of done that both sides sign off before we move on.
We don't disappear the moment the engagement closes. Managed services, hypercare windows, named on-call rotations, or quarterly health checks: pick the depth that matches your operational risk profile. About seventy percent of clients return for a second programme, usually because the team that shipped the first one is still on the other end of the page.
Anonymous under MNDA. Each quote is from a senior biotech buyer who owned the engagement end to end.
“First IND of our company that the FDA accepted on first review. The translational platform held up under questioning that would have buried us a year ago.”
Direct answers to what procurement, security, and delivery leads weigh before signing: compliance, integration, and the accountability we put in writing.
Yes. We have supported INDs across gene therapy, cell therapy, small molecule, and biologics, engineering the translational, manufacturing analytics, and CMC data platforms that the submission rests on. We sit alongside your regulatory affairs team through the agency interaction and produce the evidence pack in the format the FDA reviewers ask for.